Versartis Company Profile (NASDAQ:VSAR)

About Versartis (NASDAQ:VSAR)

Versartis logoVersartis, Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company's first indication for somavaratan is pediatric GHD. The Company may develop somavaratan for additional growth disorders, such as idiopathic short stature (ISS), small for gestational age (SGA) and Turner Syndrome. Somavaratan is engineered using XTEN technology to extend the residence time in the bloodstream by reducing the clearance of recombinant human growth hormone (rhGH) from the body by the two primary mechanisms, kidney filtration and receptor mediated clearance.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:VSAR
  • CUSIP: N/A
  • Web:
  • Market Cap: $95.31 million
  • Outstanding Shares: 35,578,000
Average Prices:
  • 50 Day Moving Avg: $18.37
  • 200 Day Moving Avg: $18.36
  • 52 Week Range: $2.60 - $24.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.92
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $2.68 per share
  • Price / Book: 1.00
  • EBIDTA: ($115,550,000.00)
  • Return on Equity: -95.78%
  • Return on Assets: -63.62%
  • Debt-to-Equity Ratio: 0.09%
  • Current Ratio: 2.39%
  • Quick Ratio: 2.39%
  • Average Volume: 336,538 shs.
  • Beta: 2.76
  • Short Ratio: 5.72

Frequently Asked Questions for Versartis (NASDAQ:VSAR)

What is Versartis' stock symbol?

Versartis trades on the NASDAQ under the ticker symbol "VSAR."

How were Versartis' earnings last quarter?

Versartis, Inc. (NASDAQ:VSAR) posted its quarterly earnings data on Thursday, July, 27th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.84) by $0.20. View Versartis' Earnings History.

When will Versartis make its next earnings announcement?

Versartis is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Versartis.

Where is Versartis' stock going? Where will Versartis' stock price be in 2017?

10 analysts have issued 12 month target prices for Versartis' stock. Their forecasts range from $3.00 to $20.00. On average, they expect Versartis' stock price to reach $7.75 in the next year. View Analyst Ratings for Versartis.

Who are some of Versartis' key competitors?

Who are Versartis' key executives?

Versartis' management team includes the folowing people:

  • Srinivas Akkaraju M.D. Ph.D., Independent Chairman of the Board
  • Jay P. Shepard, President, Chief Executive Officer, Independent Director
  • Joshua T. Brumm, Chief Financial Officer, Chief Operating Officer
  • Shane M. Ward, Senior Vice President, General Counsel
  • Jay P. Stout, Senior Vice President, Technical Operations
  • Robert Gut M.D., Ph.D., Chief Medical Officer
  • Colin Hislop M.D., Chief Medical Officer
  • Paul Westberg, Chief Business Officer
  • Tracy M. Woody, Chief Commercial Officer
  • Eric L. Dobmeier, Director

Who owns Versartis stock?

Versartis' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (10.88%), Sofinnova Management VIII L.L.C. (4.44%), Federated Investors Inc. PA (4.11%), Vanguard Group Inc. (3.18%), State Street Corp (1.56%) and Northern Trust Corp (1.19%). Company insiders that own Versartis stock include Colin Hislop, Edmon R Jennings, Jay Shepard, John Varian, Joshua T Brumm, Paul Westberg, Perceptive Advisors Llc, R Scott Greer, Shahzad Malik, Shane Ward and Srinivas Akkaraju. View Institutional Ownership Trends for Versartis.

Who sold Versartis stock? Who is selling Versartis stock?

Versartis' stock was sold by a variety of institutional investors in the last quarter, including Kingdon Capital Management L.L.C., OxFORD Asset Management LLP, FMR LLC, Arrowstreet Capital Limited Partnership, Bank of New York Mellon Corp, Russell Investments Group Ltd., Wells Fargo & Company MN and ClariVest Asset Management LLC. Company insiders that have sold Versartis stock in the last year include Colin Hislop, Edmon R Jennings, Jay Shepard, Joshua T Brumm, Paul Westberg, Shahzad Malik and Shane Ward. View Insider Buying and Selling for Versartis.

Who bought Versartis stock? Who is buying Versartis stock?

Versartis' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., TIAA CREF Investment Management LLC, Sectoral Asset Management Inc, Emory University, Ameriprise Financial Inc., Sphera Funds Management LTD., Bank of Montreal Can and Lord Abbett & CO. LLC. Company insiders that have bought Versartis stock in the last two years include Joshua T Brumm, Perceptive Advisors Llc, R Scott Greer and Srinivas Akkaraju. View Insider Buying and Selling for Versartis.

How do I buy Versartis stock?

Shares of Versartis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Versartis' stock price today?

One share of Versartis stock can currently be purchased for approximately $2.68.

MarketBeat Community Rating for Versartis (NASDAQ VSAR)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  164 (Vote Outperform)
Underperform Votes:  106 (Vote Underperform)
Total Votes:  270
MarketBeat's community ratings are surveys of what our community members think about Versartis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Versartis (NASDAQ:VSAR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.30)
Consensus Price Target: $7.75 (189.72% upside)

Analysts' Ratings History for Versartis (NASDAQ:VSAR)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/25/2017Bank of America CorporationDowngradeBuy -> NeutralMediumView Rating Details
9/25/2017Citigroup Inc.DowngradeBuy -> NeutralHighView Rating Details
9/22/2017Canaccord GenuityReiterated RatingBuy$28.00 -> $9.00N/AView Rating Details
9/22/2017Morgan StanleyReiterated RatingEqual Weight$3.00 -> $4.00N/AView Rating Details
9/22/2017Cantor FitzgeraldReiterated RatingOverweight$34.00 -> $14.00N/AView Rating Details
9/22/2017SunTrust Banks, Inc.DowngradeBuy -> Hold$25.00 -> $4.00N/AView Rating Details
9/22/2017Cowen and CompanyDowngradeOutperform -> Market Perform$45.00 -> $3.00N/AView Rating Details
9/22/2017Barclays PLCDowngradeOverweight -> Equal Weight$28.00 -> $4.00N/AView Rating Details
9/22/2017Piper Jaffray CompaniesDowngradeOverweight -> Neutral$26.00 -> $4.00N/AView Rating Details
12/20/2016Credit Suisse GroupUpgradeNeutral -> Outperform$11.00 -> $20.00N/AView Rating Details
4/7/2016Northland SecuritiesInitiated CoverageOutperformN/AView Rating Details
(Data available from 9/25/2015 forward)


Earnings History for Versartis (NASDAQ:VSAR)
Earnings by Quarter for Versartis (NASDAQ:VSAR)
Earnings History by Quarter for Versartis (NASDAQ VSAR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017($0.62)N/AView Earnings Details
7/27/2017Q2 2017($0.84)($1.04)ViewN/AView Earnings Details
4/27/2017Q1 2017($0.71)($0.85)ViewN/AView Earnings Details
2/21/2017Q4 2016($0.62)($0.64)$10.00 millionViewN/AView Earnings Details
7/28/2016Q2($0.78)($0.75)ViewN/AView Earnings Details
2/18/2016Q415($0.71)($0.69)ViewN/AView Earnings Details
10/29/2015Q3($0.79)($0.69)ViewN/AView Earnings Details
8/4/2015Q2($0.64)($0.67)ViewN/AView Earnings Details
5/6/2015($0.70)($0.79)ViewN/AView Earnings Details
2/12/2015Q414($0.53)($0.65)ViewN/AView Earnings Details
11/6/2014Q3 14($0.46)($0.57)ViewN/AView Earnings Details
5/5/2014Q114($6.37)($2.57)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Versartis (NASDAQ:VSAR)
2017 EPS Consensus Estimate: ($2.83)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.79)($0.79)($0.79)
Q2 20171($0.83)($0.83)($0.83)
Q3 20171($0.81)($0.81)($0.81)
Q4 20171($0.40)($0.40)($0.40)
(Data provided by Zacks Investment Research)


Dividend History for Versartis (NASDAQ:VSAR)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Versartis (NASDAQ:VSAR)
Insider Ownership Percentage: 9.60%
Institutional Ownership Percentage: 78.24%
Insider Trades by Quarter for Versartis (NASDAQ:VSAR)
Institutional Ownership by Quarter for Versartis (NASDAQ:VSAR)
Insider Trades by Quarter for Versartis (NASDAQ:VSAR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/13/2017Joshua T BrummCFOSell1,421$16.05$22,807.05View SEC Filing  
6/13/2017Paul WestbergSVPSell711$16.05$11,411.55View SEC Filing  
5/16/2017Joshua T. BrummCFOSell1,263$17.40$21,976.20View SEC Filing  
4/19/2017Paul WestbergSVPSell1,316$19.85$26,122.60View SEC Filing  
4/4/2017Colin HislopInsiderSell35,000$21.20$742,000.00View SEC Filing  
3/24/2017Srinivas AkkarajuDirectorBuy571,429$12.25$7,000,005.25View SEC Filing  
3/17/2017Shahzad MalikDirectorSell483,670$18.11$8,759,263.70View SEC Filing  
3/15/2017Shahzad MalikDirectorSell166,330$19.09$3,175,239.70View SEC Filing  
3/15/2017Shane WardSVPSell2,041$19.01$38,799.41View SEC Filing  
2/27/2017Jay ShepardInsiderSell5,166$24.00$123,984.00View SEC Filing  
2/27/2017Paul WestbergSVPSell12,500$22.50$281,250.00View SEC Filing  
2/23/2017Jay ShepardInsiderSell16,000$19.25$308,000.00View SEC Filing  
2/23/2017Paul WestbergSVPSell25,000$18.75$468,750.00View SEC Filing  
2/13/2017Perceptive Advisors LlcMajor ShareholderBuy94,016$15.30$1,438,444.80View SEC Filing  
2/9/2017Perceptive Advisors LlcMajor ShareholderBuy145,823$13.72$2,000,691.56View SEC Filing  
2/3/2017Jay ShepardInsiderSell6,719$13.69$91,983.11View SEC Filing  
2/2/2017Jay ShepardInsiderSell24,211$13.77$333,385.47View SEC Filing  
1/30/2017Jay ShepardInsiderSell17,270$13.52$233,490.40View SEC Filing  
1/30/2017Joshua T BrummCFOSell2,945$13.85$40,788.25View SEC Filing  
1/30/2017Paul WestbergSVPSell1,916$13.85$26,536.60View SEC Filing  
1/11/2017Paul WestbergVPSell7,931$15.24$120,868.44View SEC Filing  
1/10/2017Paul WestbergVPSell11,213$15.66$175,595.58View SEC Filing  
1/9/2017Paul WestbergVPSell13,356$15.93$212,761.08View SEC Filing  
12/30/2016Perceptive Advisors LlcMajor ShareholderBuy94,750$14.66$1,389,035.00View SEC Filing  
12/29/2016Perceptive Advisors LlcMajor ShareholderBuy47,375$14.37$680,778.75View SEC Filing  
12/27/2016Joshua T BrummCFOSell990$15.85$15,691.50View SEC Filing  
12/27/2016Paul WestbergVPSell361$15.85$5,721.85View SEC Filing  
12/16/2016Paul WestbergVPSell5,000$15.00$75,000.00View SEC Filing  
12/8/2016Edmon R JenningsDirectorSell1,500$12.96$19,440.00View SEC Filing  
12/7/2016Joshua T BrummCFOSell3,021$13.25$40,028.25View SEC Filing  
10/3/2016Srinivas AkkarajuDirectorBuy571,429$12.25$7,000,005.25View SEC Filing  
8/25/2016John VarianDirectorSell1,600$12.97$20,752.00View SEC Filing  
8/22/2016Jay ShepardCEOSell5,442$12.88$70,092.96View SEC Filing  
6/15/2016Joshua T BrummCFOSell1,448$10.63$15,392.24View SEC Filing  
6/15/2016Paul WestbergVPSell725$10.63$7,706.75View SEC Filing  
5/20/2016Joshua T BrummCFOSell1,265$7.87$9,955.55View SEC Filing  
4/21/2016Paul WestbergVPSell1,430$9.68$13,842.40View SEC Filing  
12/30/2015Joshua T BrummCFOSell990$12.44$12,315.60View SEC Filing  
12/30/2015Paul WestbergVPSell362$12.44$4,503.28View SEC Filing  
11/12/2015Joshua T BrummCFOBuy2,500$9.99$24,975.00View SEC Filing  
11/11/2015R Scott GreerDirectorBuy10,000$10.17$101,700.00View SEC Filing  
7/6/2015Paul WestbergVPSell2,400$15.00$36,000.00View SEC Filing  
6/3/2015Paul WestbergVPSell2,400$16.73$40,152.00View SEC Filing  
5/4/2015Paul WestbergVPSell2,400$17.47$41,928.00View SEC Filing  
4/14/2015Jeffrey L ClelandCEOSell8,000$20.13$161,040.00View SEC Filing  
4/6/2015Paul WestbergVPSell2,400$17.49$41,976.00View SEC Filing  
3/23/2015Jeffrey L ClelandCEOSell4,000$20.26$81,040.00View SEC Filing  
3/20/2015Jeffrey L ClelandCEOSell3,179$20.03$63,675.37View SEC Filing  
3/10/2015Jeffrey L ClelandCEOSell4,000$20.23$80,920.00View SEC Filing  
3/2/2015Jeffrey L ClelandCEOSell2,871$20.11$57,735.81View SEC Filing  
2/3/2015Paul WestbergVPSell5,000$17.40$87,000.00View SEC Filing  
1/27/2015Aisling Capital Iii LpMajor ShareholderBuy145,000$17.25$2,501,250.00View SEC Filing  
1/27/2015R Scott GreerDirectorBuy5,500$17.25$94,875.00View SEC Filing  
1/22/2015Shahzad MalikDirectorBuy55,000$17.25$948,750.00View SEC Filing  
1/12/2015Jeffrey L ClelandCEOSell4,000$22.85$91,400.00View SEC Filing  
1/5/2015Jeffrey L ClelandCEOSell4,000$21.94$87,760.00View SEC Filing  
1/5/2015Paul WestbergVPSell5,000$22.48$112,400.00View SEC Filing  
12/29/2014Jeffrey L ClelandCEOSell4,000$22.11$88,440.00View SEC Filing  
12/22/2014Jeffrey L ClelandCEOSell8,000$21.14$169,120.00View SEC Filing  
12/18/2014Leaf Ventures Ii L.P. NewMajor ShareholderSell150,000$19.01$2,851,500.00View SEC Filing  
12/12/2014Paul WestbergVPSell10,000$18.55$185,500.00View SEC Filing  
11/24/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell17,207$18.02$310,070.14View SEC Filing  
11/21/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell26,793$18.04$483,345.72View SEC Filing  
11/20/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell9,000$18.32$164,880.00View SEC Filing  
11/18/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell191,362$19.38$3,708,595.56View SEC Filing  
11/13/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell12,438$19.43$241,670.34View SEC Filing  
11/12/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell36,200$19.42$703,004.00View SEC Filing  
9/29/2014Leaf Ventures Ii L.P. NewMajor ShareholderSell12,556$20.02$251,371.12View SEC Filing  
3/27/2014Leaf Ventures Ii L.P. NewDirectorBuy60,000$21.02$1,261,200.00View SEC Filing  
3/26/2014Aisling Capital Iii LpMajor ShareholderBuy60,000$21.00$1,260,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Versartis (NASDAQ:VSAR)
Latest Headlines for Versartis (NASDAQ:VSAR)
DateHeadline logoIs Versartis Inc (VSAR) Undervalued? - September 23 at 10:53 AM logoHuman Growth Drug Flop Sends This Biotech Crashing 83% - September 23 at 10:53 AM logoAscendis Pharma shares surge 42% on competitor's flop - September 23 at 10:53 AM logoVersartis Inc. (VSAR) Is Plummeting After Phase 3 Study Failed - September 23 at 10:53 AM logoVersartis shares down 82% - September 23 at 10:53 AM logoVersartis, Inc. (VSAR) Downgraded to "Strong Sell" at ValuEngine - September 22 at 11:34 PM logoVersartis, Inc. (VSAR) PT Lowered to $9.00 at Canaccord Genuity - September 22 at 3:14 PM logoVersartis, Inc. (VSAR) Downgraded to Neutral at Piper Jaffray Companies - September 22 at 12:40 PM logoVersartis, Inc. (VSAR) Lowered to Underweight at Barclays PLC - September 22 at 12:40 PM logoCowen and Company Downgrades Versartis, Inc. (VSAR) to Market Perform - September 22 at 11:58 AM logoVersartis, Inc. (VSAR) Stock Rating Lowered by SunTrust Banks, Inc. - September 22 at 9:18 AM logoVersartis, Inc. (VSAR) Earns "Equal Weight" Rating from Morgan Stanley - September 22 at 9:18 AM logoVersartis, Inc. (VSAR) PT Lowered to $14.00 - September 22 at 9:18 AM logoNotable Thursday Option Activity: VMC, LGIH, VSAR - September 15 at 11:15 AM logoFinancial Contrast: Versartis (VSAR) versus its Peers - September 11 at 1:06 PM logoVersartis, Inc. (VSAR) Rating Reiterated by Piper Jaffray Companies - September 8 at 6:44 PM logoVersartis’ Twice-Monthly Somavaratan for Pediatric Growth Hormone Deficiency to be Featured in Oral and Poster Presentations at IMPE 2017 - September 8 at 10:07 AM logoVersartis Announces Expansion of Executive Leadership Team with Addition of Dr. Robert Gut as the Head of Global Clinical, Medical and Regulatory Affairs - September 6 at 10:04 AM logoVersartis, Inc. (VSAR) Given Consensus Recommendation of "Buy" by Brokerages - September 5 at 6:28 AM logoValuEngine Upgrades Versartis, Inc. (VSAR) to "Hold" - September 2 at 12:06 AM logoImplied Volatility Surging for Versartis (VSAR) Stock Options - September 1 at 10:54 AM logoVersartis, Inc. (VSAR) Upgraded to Hold at Zacks Investment Research - August 30 at 11:36 AM logoCantor Fitzgerald Weighs in on Versartis, Inc.'s FY2017 Earnings (VSAR) - August 28 at 2:02 AM logoBiotech Forum Daily Digest: An Update On Versartis Before Key Trial Data - August 23 at 11:44 PM logoCowen and Company Reiterates "Outperform" Rating for Versartis, Inc. (VSAR) - August 23 at 1:10 PM logoVersartis, Inc. (VSAR) Expected to Post Earnings of -$0.68 Per Share - August 23 at 8:12 AM logoValuEngine Lowers Versartis, Inc. (VSAR) to Sell - August 17 at 10:40 PM logoVersartis, Inc. (NASDAQ:VSAR) Receives Consensus Recommendation of "Buy" from Brokerages - August 11 at 3:24 PM logo Brokerages Expect Versartis, Inc. (VSAR) Will Post Earnings of -$0.68 Per Share - August 5 at 7:08 AM logoOptions Traders Expect Huge Moves in Versartis (VSAR) Stock - August 4 at 9:48 AM logoVersartis Inc (NASDAQ:VSAR) Rating Lowered to Hold at BidaskClub - August 2 at 5:12 PM logoVersartis to Present at the Canaccord Genuity Growth Conference - August 2 at 8:33 AM logoBrokers Offer Predictions for Versartis, Inc.'s FY2021 Earnings (NASDAQ:VSAR) - July 31 at 10:36 AM logoVersartis, Inc. (VSAR) Posts Earnings Results, Misses Expectations By $0.20 EPS - July 28 at 4:28 PM logoCanaccord Genuity Analysts Give Versartis, Inc. (VSAR) a $28.00 Price Target - July 28 at 2:08 PM logoVersartis Reports Second Quarter 2017 Financial Results - July 28 at 9:46 AM logoVersartis reports 2Q loss - July 28 at 9:46 AM logoVersartis, Inc. (VSAR) Given a $34.00 Price Target at Cantor Fitzgerald - July 27 at 6:43 PM logoVersartis, Inc. (VSAR) Lifted to "Buy" at BidaskClub - July 24 at 11:32 PM logoVersartis, Inc. (VSAR) to Release Quarterly Earnings on Wednesday - July 19 at 8:15 AM logoVersartis, Inc. (NASDAQ:VSAR) Receives Average Recommendation of "Buy" from Brokerages - July 17 at 10:48 AM logoVersartis, Inc. (NASDAQ:VSAR) Downgraded by BidaskClub to Hold - July 16 at 8:16 PM logo-$0.84 EPS Expected for Versartis, Inc. (NASDAQ:VSAR) This Quarter - July 13 at 10:23 PM logoVersartis, Inc. (VSAR) Upgraded to "Hold" by Zacks Investment Research - June 29 at 11:54 AM logoAnalysts Offer Predictions for Versartis, Inc.'s FY2018 Earnings (VSAR) - June 26 at 7:51 AM logoIs the Options Market Predicting a Spike in Versartis (VSAR) Stock? - June 22 at 2:37 PM logoVersartis, Inc. (VSAR) Given Average Rating of "Buy" by Analysts - June 20 at 8:07 AM logoVersartis, Inc. (VSAR) Expected to Post Earnings of -$0.84 Per Share - June 19 at 10:30 PM logoVersartis, Inc. (VSAR) CFO Joshua T. Brumm Sells 1,421 Shares - June 14 at 8:34 PM logoInsider Selling: Versartis, Inc. (VSAR) SVP Sells 711 Shares of Stock - June 14 at 8:32 PM



Versartis (VSAR) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by Staff